Harrow Announces Second Quarter 2023 Financial Results
Second Quarter 2023 and Recent Selected Highlights:
- Record revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase of 28% over $26.1 million in the sequential quarter.
- GAAP net loss of ($4.2) million.
- Record adjusted EBITDA of $11.0 million, an increase of 144% over $4.5 million in the prior‑year quarter and an increase of 108% over $5.3 million in the sequential quarter.
- Completed public offering of common stock for aggregate gross proceeds of $69 million.
- Expanded Oaktree Loan from $100 million to $112.50 million.
- Acquired certain commercial rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands FRESHKOTE® and Cationorm® PLUS.
- Acquired North American commercial rights to VEVYE®, a novel FDA-approved drug labeled to treat both the signs and symptoms of dry eye disease.
- Completed transfer of New Drug Application for VIGAMOX®.
NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the second quarter and six months ended June 30, 2023. The Company also posted its second quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com.
“Our team has made great progress positioning Harrow as a top-tier U.S.-focused ophthalmic pharmaceutical company,” said Mark L. Baum, CEO of Harrow. “Since January of 2023, through a series of transactions, we have not only improved Harrow’s balance sheet, but we’ve dramatically improved Harrow’s product portfolio, which is now one of the most comprehensive ophthalmic pharmaceutical offerings in the U.S. market. With what we now have in our “bag” and continued execution and operational performance by the Harrow team, we believe we are on our way to achieving the highest financial goals for Harrow’s stockholders.”
Second quarter 2023 figures of merit:
|
For the Three Months Ended
|
|
For the Six Months Ended
| |||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | |||||||||
Net revenues | $ | 33,470,000 |
| $ | 23,323,000 |
| $ | 59,573,000 |
| $ | 45,443,000 |
| ||||
Gross margin |
| 70 | % |
| 72 | % |
| 69 | % |
| 72 | % | ||||
Core gross margin(1) |
| 78 | % |
| 73 | % |
| 77 | % |
| 74 | % | ||||
Net loss |
| (4,229,000 | ) |
| (6,239,000 | ) |
| (10,872,000 | ) |
| (8,677,000 | ) | ||||
Core net (loss) income(1) |
| (494,000 | ) |
| 254,000 |
|
| (1,536,000 | ) |
| 967,000 |
| ||||
Adjusted EBITDA(1) |
| 11,005,000 |
|
| 4,505,000 |
|
| 16,347,000 |
|
| 9,445,000 |
| ||||
Basic net loss per share |
| (0.14 | ) |
| (0.23 | ) |
| (0.36 | ) |
| (0.32 | ) | ||||
Diluted net loss per share |
| (0.14 | ) |
| (0.23 | ) |
| (0.36 | ) |
| (0.32 | ) | ||||
Core basic net (loss) income per share(1) |
| (0.02 | ) |
| 0.01 |
|
| (0.05 | ) |
| 0.04 |
| ||||
Core diluted net (loss) income per share(1) |
| (0.02 | ) |
| 0.01 |
|
| (0.05 | ) |
| 0.03 |
| ||||
(1) | Core gross margin, core net (loss) income, core basic and diluted net (loss) income per share (collectively, “Core Results”), and Adjusted EBITDA are non GAAP measures. For additional information, including a reconciliation of such Core Results and Adjusted EBITDA to the most directly comparable measures presented in accordance with GAAP, see the explanation of non-GAAP measures and reconciliation tables in the financial tables section. |
Conference Call and Webcast
The Company’s management team will host a conference call and live webcast today at 4:45 p.m. Eastern Time to discuss the second quarter 2023 results and provide a business update. To participate in the call, see details below:
Conference Call Details: |
|
Date: | Wednesday, August 9, 2023 |
Time: | 4:45 p.m. Eastern time |
Participant Dial-in: |
1-833-953-2434 (U.S.)
|
Replay Dial-in (Passcode 3750229): (telephonic replay through August 16, 2023) |
1-877-344-7529 (U.S.)
|
Webcast: (online replay through August 9, 2024) |
About Harrow
Harrow Health, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. Harrow helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans each year. For more information about Harrow, please visit harrow.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward-looking statements.” Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
HARROW HEALTH, INC. CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
|
June 30,
|
December 31,
| ||||
(unaudited) | ||||||
ASSETS | ||||||
Cash and cash equivalents | $ | 22,754,000 | $ | 96,270,000 | ||
All other current assets |
| 37,542,000 |
| 21,990,000 | ||
Total current assets |
| 60,296,000 |
| 118,260,000 | ||
All other assets |
| 163,693,000 |
| 39,118,000 | ||
TOTAL ASSETS | $ | 223,989,000 | $ | 157,378,000 | ||
| ||||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
Current liabilities | $ | 23,011,000 | $ | 18,632,000 | ||
Loans payable, net of current portion and unamortized debt discount |
| 169,712,000 |
| 104,174,000 | ||
All other liabilities |
| 9,214,000 |
| 7,332,000 | ||
TOTAL LIABILITIES |
| 201,937,000 |
| 130,138,000 | ||
TOTAL STOCKHOLDERS' EQUITY |
| 22,052,000 |
| 27,240,000 | ||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 223,989,000 | $ | 157,378,000 | ||
HARROW HEALTH, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
|
For the Three Months Ended
|
|
For the Six Months Ended
| |||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | |||||||||
Total revenues | $ | 33,470,000 |
| $ | 23,323,000 |
| $ | 59,573,000 |
| $ | 45,443,000 |
| ||||
Cost of sales |
| 10,000,000 |
|
| 6,534,000 |
|
| 18,271,000 |
|
| 12,497,000 |
| ||||
Gross profit |
| 23,470,000 |
|
| 16,789,000 |
|
| 41,302,000 |
|
| 32,946,000 |
| ||||
Selling, general and administrative |
| 19,957,000 |
|
| 14,185,000 |
|
| 35,845,000 |
|
| 27,583,000 |
| ||||
Research and development |
| 1,161,000 |
|
| 914,000 |
|
| 1,895,000 |
|
| 1,572,000 |
| ||||
Total operating expenses |
| 21,118,000 |
|
| 15,099,000 |
|
| 37,740,000 |
|
| 29,155,000 |
| ||||
Income from operations |
| 2,352,000 |
|
| 1,690,000 |
|
| 3,562,000 |
|
| 3,791,000 |
| ||||
Total other expense, net |
| 6,596,000 |
|
| 7,889,000 |
|
| 14,737,000 |
|
| 12,428,000 |
| ||||
Income tax benefit (expense) |
| 15,000 |
|
| (40,000 | ) |
| 303,000 |
|
| (40,000 | ) | ||||
Net loss attributable to Harrow Health, Inc. | $ | (4,229,000 | ) | $ | (6,239,000 | ) | $ | (10,872,000 | ) | $ | (8,677,000 | ) | ||||
Net loss per share of common stock, basic and diluted | $ | (0.14 | ) | $ | (0.23 | ) | $ | (0.36 | ) | $ | (0.32 | ) | ||||
HARROW HEALTH, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| ||||||||
For the Six Months Ended June 30, | ||||||||
2023 |
| 2022 | ||||||
Net cash (used in) provided by: |
|
| ||||||
Operating activities | $ | (3,648,000 | ) | $ | 5,827,000 |
| ||
Investing activities |
| (132,219,000 | ) |
| (669,000 | ) | ||
Financing activities |
| 62,351,000 |
|
| (887,000 | ) | ||
Net change in cash and cash equivalents |
| (73,516,000 | ) |
| 4,271,000 |
| ||
Cash and cash equivalents at beginning of the period |
| 96,270,000 |
|
| 42,167,000 |
| ||
Cash and cash equivalents at end of the period | $ | 22,754,000 |
| $ | 46,438,000 |
| ||
Non-GAAP Financial Measures
In addition to the Company’s results of operations determined in accordance with U.S. generally accepted accounting principles (GAAP), which are presented and discussed above, management also utilizes Adjusted EBITDA and Core Results, unaudited financial measures that are not calculated in accordance with GAAP, to evaluate the Company’s financial results and performance and to plan and forecast future periods. Adjusted EBITDA and Core Results are considered “non‑GAAP” financial measures within the meaning of Regulation G promulgated by the SEC. Management believes that these non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results, provide a more complete understanding of the Company’s results of operations and the factors and trends affecting its business. Management believes Adjusted EBITDA and Core Results provide meaningful supplemental information regarding the Company’s performance because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making; (ii) they exclude the impact of non-cash or, when specified, non-recurring items that are not directly attributable to the Company’s core operating performance and that may obscure trends in the Company’s core operating performance; and (iii) they are used by institutional investors and the analyst community to help analyze the Company’s results. However, Adjusted EBITDA, Core Results, and any other non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Further, non‑GAAP financial measures used by the Company and the way they are calculated may differ from the non-GAAP financial measures or the calculations of the same non‑GAAP financial measures used by other companies, including the Company’s competitors.
Adjusted EBITDA
The Company defines Adjusted EBITDA as net (loss) income, excluding the effects of stock‑based compensation and expenses, interest, taxes, depreciation, amortization, investment (loss) income, net, and, if any and when specified, other non-recurring income or expense items. Management believes that the most directly comparable GAAP financial measure to Adjusted EBITDA is net (loss) income. Adjusted EBITDA has limitations and should not be considered as an alternative to gross profit or net (loss) income as a measure of operating performance or to net cash provided by (used in) operating, investing, or financing activities as a measure of ability to meet cash needs.
The following is a reconciliation of Adjusted EBITDA, a non-GAAP measure, to the most comparable GAAP measure, net loss, for the three months and six months ended June 30, 2023, and for the same periods in 2022:
HARROW HEALTH, INC. RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA | |||||||||||||||
|
For the Three Months Ended
|
|
For the Six Months Ended
| ||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
GAAP net loss | $ | (4,229,000 | ) | $ | (6,239,000 | ) | $ | (10,872,000 | ) | $ | (8,677,000 | ) | |||
Stock-based compensation and expenses |
| 5,412,000 |
|
| 1,993,000 |
|
| 7,045,000 |
|
| 4,009,000 |
| |||
Interest expense, net |
| 5,704,000 |
|
| 1,794,000 |
|
| 10,451,000 |
|
| 3,586,000 |
| |||
Income tax expense (benefit) |
| (15,000 | ) |
| 40,000 |
|
| (303,000 | ) |
| 40,000 |
| |||
Depreciation |
| 398,000 |
|
| 424,000 |
|
| 690,000 |
|
| 843,000 |
| |||
Amortization of intangible assets |
| 2,843,000 |
|
| 398,000 |
|
| 5,050,000 |
|
| 802,000 |
| |||
Investment loss (income), net |
| 714,000 |
|
| 6,095,000 |
|
| (1,328,000 | ) |
| 8,842,000 |
| |||
Other expense, net |
| 178,000 |
|
| - |
|
| 5,614,000 | (1) |
| - |
| |||
Adjusted EBITDA | $ | 11,005,000 |
| $ | 4,505,000 |
| $ | 16,347,000 |
| $ | 9,445,000 |
| |||
(1) | Includes $5,465,000 for the loss on extinguishment of debt. |
Core Results
Harrow Core Results, including core gross margin, core net income (loss), core operating income, core basic and diluted income (loss) per share, and core operating margin, exclude all amortization and impairment charges of intangible assets, excluding software development costs, net gains and losses on investments and equity securities, including equity method gains and losses and equity valued at fair value through profit and loss (“FVPL”), preferred stock dividends, and gains/losses on forgiveness of debt. In other periods, Core Results may also exclude fair value adjustments of financial assets in the form of options to acquire a company carried at FVPL, obligations related to product recalls, certain acquisition‑related items, restructuring charges/releases and associated items, related legal items, gains/losses on early extinguishment of debt or debt modifications, impairments of property, plant and equipment and software, as well as income and expense items that management deems exceptional and that are or are expected to accumulate within the year to be over a $100,000 threshold.
The following is a reconciliation of Core Results, non-GAAP measures, to the most comparable GAAP measures for the three and six months ended June 30, 2023, and for the same periods in 2022:
For the Three Months Ended June 30, 2023 | |||||||||||||||||
GAAP Results | Amortization of Certain Intangible Assets | Investment Gains | Other Items | Core Results | |||||||||||||
Gross profit | $ | 23,470,000 |
| $ | 2,649,000 | $ | - | $ | - | $ | 26,119,000 |
| |||||
Gross margin |
| 70 | % |
|
|
|
| 78 | % | ||||||||
Operating income |
| 2,352,000 |
|
| 2,843,000 |
| - |
| - |
| 5,195,000 |
| |||||
(Loss) income before taxes |
| (4,244,000 | ) |
| 2,843,000 |
| 714,000 |
| 178,000 |
| (509,000 | ) | |||||
Tax benefit |
| 15,000 |
|
| - |
| - |
| - |
| 15,000 |
| |||||
Net (loss) income |
| (4,229,000 | ) |
| 2,843,000 |
| 714,000 |
| 178,000 |
| (494,000 | ) | |||||
Basic and diluted loss per share ($)(1) |
| (0.14 | ) |
|
|
|
| (0.02 | ) | ||||||||
Weighted average number of shares of common stock outstanding, basic and diluted |
| 30,458,677 |
|
|
| 30,458,677 |
| ||||||||||
For the Six Months Ended June 30, 2023 | ||||||||||||||||||
GAAP Results | Amortization of Certain Intangible Assets | Investment Losses | Other Items | Core Results | ||||||||||||||
Gross profit | $ | 41,302,000 |
| $ | 4,694,000 | $ | - |
| $ | - | $ | 45,996,000 |
| |||||
Gross margin |
| 69 | % |
|
|
|
| 77 | % | |||||||||
Operating income |
| 3,562,000 |
|
| 5,050,000 |
| - |
|
| - |
| 8,612,000 |
| |||||
(Loss) income before taxes |
| (11,175,000 | ) |
| 5,050,000 |
| (1,328,000 | ) |
| 5,614,000 |
| (1,839,000 | ) | |||||
Tax benefit |
| 303,000 |
|
| - |
| - |
|
| - |
| 303,000 |
| |||||
Net (loss) income |
| (10,872,000 | ) |
| 5,050,000 |
| (1,328,000 | ) |
| 5,614,000 |
| (1,536,000 | ) | |||||
Basic and diluted loss per share ($)(1) |
| (0.36 | ) |
|
|
|
| (0.05 | ) | |||||||||
Weighted average number of shares of common stock outstanding, basic and diluted |
| 30,379,354 |
|
|
|
|
| 30,379,354 |
| |||||||||
For the Three Months Ended June 30, 2022 | ||||||||||||||
GAAP Results | Amortization of Certain Intangible Assets | Investment Gains | Core Results | |||||||||||
Gross profit | $ | 16,789,000 |
| $ | 341,000 | $ | - | $ | 17,130,000 |
| ||||
Gross margin |
| 72 | % |
|
|
| 73 | % | ||||||
Operating income |
| 1,690,000 |
|
| 398,000 |
| - |
| 2,088,000 |
| ||||
(Loss) income before taxes |
| (6,199,000 | ) |
| 398,000 |
| 6,095,000 |
| 294,000 |
| ||||
Taxes |
| (40,000 | ) |
| - |
| - |
| (40,000 | ) | ||||
Net (loss) income |
| (6,239,000 | ) |
| 398,000 |
| 6,095,000 |
| 254,000 |
| ||||
Basic (loss) earnings per share ($)(1) |
| (0.23 | ) |
| 0.01 |
| ||||||||
Diluted (loss) earnings per share ($)(1) |
| (0.23 | ) |
| 0.01 |
| ||||||||
Weighted average number of shares of common stock outstanding: |
|
|
|
| ||||||||||
Basic |
| 27,303,458 |
|
| 27,303,458 |
| ||||||||
Diluted |
| 27,303,458 |
|
| 28,234,177 |
| ||||||||
For the Six Months Ended June 30, 2022 | ||||||||||||||
GAAP Results | Amortization of Certain Intangible Assets | Investment Gains | Core Results | |||||||||||
Gross profit | $ | 32,946,000 |
| $ | 682,000 | $ | - | $ | 33,628,000 |
| ||||
Gross margin |
| 72 | % |
|
|
| 74 | % | ||||||
Operating income |
| 3,791,000 |
|
| 802,000 |
| - |
| 4,593,000 |
| ||||
(Loss) Income before taxes |
| (8,637,000 | ) |
| 802,000 |
| 8,842,000 |
| 1,007,000 |
| ||||
Taxes |
| (40,000 | ) |
| - |
| - |
| (40,000 | ) | ||||
Net (loss) income |
| (8,677,000 | ) |
| 802,000 |
| 8,842,000 |
| 967,000 |
| ||||
Basic (loss) earnings per share ($)(1) |
| (0.32 | ) |
| 0.04 |
| ||||||||
Diluted (loss) earnings per share ($)(1) |
| (0.32 | ) |
| 0.03 |
| ||||||||
Weighted average number of shares of common stock outstanding: |
|
|
|
| ||||||||||
Basic |
| 27,265,350 |
|
| 27,265,350 |
| ||||||||
Diluted |
| 27,265,350 |
|
| 28,270,639 |
| ||||||||
(1) | Core basic and diluted (loss) earnings per share is calculated using the weighted-average number of shares of common stock outstanding during the period. Core basic and diluted (loss) earnings per share also contemplates dilutive shares associated with equity-based awards as described in Note 2 and elsewhere in the Condensed Consolidated Financial Statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023. |
Contacts
Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737
Editor Details
-
Company:
- Businesswire
